ARTHUR-D.-LITTLE
11.1.2021 15:33:34 CET | Business Wire | Press release
Arthur D. Little (ADL) today announced that it has been awarded multiple high impact projects by the European Space Agency (ESA) to help identify the most promising services for next generation satellite communication (SatCom) infrastructure. ADL will conduct a major consultation process with key members of the transport, energy, infrastructure and media industries, plus stakeholders in law enforcement and emergency services, to identify and assess potential applications and services that could be delivered via satellite in the next decade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005719/en/
ADL will be responsible for four studies in total. Three of the studies are part of the Advanced Research in Telecommunications Systems (ARTES) 4.0 Strategic Programme Line “Space Systems for Safety and Security” (4S), and are supported by the Italian Space Agency:
- Safety of Future Transport
- Safeguarding Essential Services
- Satellite Applications for Public Safety
As part of its ‘Open Consulting’ approach, ADL will conduct these studies with input from Distretto Tecnologico Aerospaziale (DTA).
The fourth study is an ARTES4.0 Business Applications Feasibility Study and is supported by the Norwegian Space Agency:
- Port of the Future
ADL will conduct this study in collaboration with Marlink and CLS.
With society and the economy dependent on telecommunications networks, the aim of 4S is to support the development of secure SatCom systems to both improve digital infrastructure resilience across Europe and the rest of the world, and provide innovative services and solutions. As terrestrial networks become increasingly vulnerable to disruption and attack, integrating next generation SatCom systems with the existing digital infrastructure can help make these networks more resilient and secure.
The Safety of Future Transport study will focus on how next generation SatCom solutions can increase safety and efficiency in the fast-evolving aviation, maritime and railway sectors, with potential applications relating to unmanned aircraft and ships, and automated traffic management systems. Safeguarding Essential Services will focus on how SatCom can help protect critical infrastructure such as energy utilities as well as public media. Satellite Applications for Public Safety will focus on how SatCom can supplement and support existing Public Protection and Disaster Relief (PPDR) networks used by first responders such as the police, fire brigade, health services and search & rescue.
The Port of the Future study will assess the technical feasibility and economic viability of new Earth observation and SatCom-based services for the port industry, focusing not only on operations of the port itself, but also on monitoring their environmental impact in terms of air and water quality.
Francesco Marsella, Managing Partner and Global S&O Practice Leader at ADL , comments: "SatCom has an increasingly vital role to play in protecting our society and making its infrastructure more secure and resilient. As terrestrial networks become more prone to failure, whether due to natural disaster or cyberattack, SatComs can support and maintain European telecoms systems. These studies will be key to developing existing satellite systems and identifying the services of the future.”
Lars Thurmann-Moe, Managing Partner, ADL Norway , comments: “It is not always appreciated quite how important the maritime sector remains, with the great majority of goods still transported by sea. SatCom is already central to modern maritime operations in terms of communication and navigation, but there is still so much more that can be done to improve these operations, and also reduce the industry’s environmental footprint – for instance, helping to quickly pinpoint oil spillages.”
Matteo Ainardi, Head of the Aerospace & Defense Competence Center at ADL , comments: "The satellite industry is today being disrupted by the introduction of new technologies such as large scale low earth orbit (LEO) constellations, reusable launchers and phased-array antennas. It is the right time to assess the evolving demand for SatCom solutions, and develop a next generation SatCom capability that can leverage these major technological breakthroughs to the benefit of the European society and economy. ADL is highly involved in the commercial space sector – as such, we are very pleased to be working with ESA on these studies, and look forward to applying our industry expertise to help define the SatCom-based services and applications of the future.”
To find out more about Arthur D. Little’s work in the space industry, please visit www.adlittle.com/en/industries/aerospace-defense
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005719/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
